Aclarion, a healthcare technology company, has announced the launch of Nociscan 2.6, a product utilizing biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying the location of chronic low back pain (cLBP). This release includes support for additional leading magnetic resonance imaging (MRI) scanners, expanding Nociscan's accessibility beyond Siemens-manufactured machines.

Previously, MRI compatibility with Nociscan was limited to Siemens machines, and this release marks a significant technical achievement. The expanded compatibility is expected to increase access to Nociscan for healthcare providers and patients worldwide. Siemens, a major player in the MRI market, had constrained the availability of Nociscan in certain markets until now.

Nociscan aims to address the global healthcare challenge of degenerative spine disease and low back pain, affecting approximately 266 million people. Aclarion's mission is to redefine spinal diagnostics, with Nociscan positioned as the standard decision support tool for diagnosing and treating chronic low back pain.

The advancement of augmented intelligence decision support solutions, exemplified by Nociscan, is making a positive impact on the lives of millions of patients. Aclarion takes pride in leading the industry in tackling this widespread healthcare problem and is dedicated to transforming the diagnostic approach to chronic low back pain.

Source: globenewswire.com